Figure S3 - PLOS

Recommend Documents

Figure S3. Neutralization titres against H1N1pdm. The location of each pie chart indicates neutralization tire at baseline (x-axis) and at follow-up (y-axis).

Figure S3 - PLOS

Page 1. BRCA1. FANCA. BARD1. CHK2. BRCA2. FANCF. ERBB2. FANCD2. FANCB. TP53. MLH1. ITGB3BP. Figure S3.

Figure S3 - PLOS

Page 1. 0. 10. 20. 30. 40. 50. 60. 70. HIF004Bay x. HIF004Sha. R e la tive. P rim a ry R o o t le n g th. (%. ) HIF004Bay. HIF004Sha a a b. Figure S3.

Figure S3 - PLOS

Mobility of TTDA with and without actD. 0. 10. 20. 30. 40. 50. 0.4. 0.6. 0.8. 1.0. Time (sec.) R e la tiv e flu o rescenc e. Figure S3.

figure s3 - PLOS

FIGURE S3. Homer la Knockout. Oh. 48 h. 200%. |. UH. NREM Delta %. Days. 20 IL. 09%. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15. Interval. --WT HE HET O-KO.

Figure S3 - PLOS

Figure S3. - PLOS

Figure S3 - PLOS

Figure S3. - PLOS

DQ138152 VIET NAMA/CHICKEN/VIET NAM/TG-023/2004 GALLIFORMES. DQ138153 VIET NAM A/CHICKEN/VIETNAM/LA-024/2004 GALLIFORMES.

Figure S3 - PLOS

Supplementary Figure S3 - PLOS

Figure S3.pptx - PLOS

C. D. 1. 4. /1. 9. A le x a. -7. 0. 0. 0. 0. 50K. 100K. 150K. 200K. 250K. SSC-A. 85.5. 0. 10 3. 10 4. 10 5. C. D. 3. A. P. C. -H. 7. 0. 50K. 100K. 150K. 200K. 250K.

Figure S3 - PLOS

1.0. 0.9. 0.8. 0.7. 0.6. 0.5. 0.4. 0.3. 0.2. 0.1. 0. 10-3. 10-2. 10-1. 100. 101. 102. 103. Legend. Log10(S15) (nM). Fraction B ound. Rr-mRNA. 1.0. 0.9. 0.8. 0.7. 0.6.

Figure S3 - PLOS

ABCDE Figure S3 - PLOS

All coasts, with Chipewyan, Cree, Ojibwa, Ache, Guarani, Kaingang excluded. 0. 0.1. 0.2. 0.3. 0.4. 0.5. 1: 0. 0. 5. 1: 0. 0. 4. 1: 0. 0. 3. 1: 0. 0. 2. 1: 0. 0. 1. 1: 0. 5. 1:.

Figure S3 - PLOS

3. 4. 5. 6. 7. 8. 0.50. 0.75. 1.00. 1.25. 1.50. Peak 2b. Peak 2a. AUC =Area under the curve. Peak 1. Age in months. A. UC. (A. U). Figure S3. 0. 5. 10. 15. 20. 25. 0.

Figure S3. - PLOS

Figure S3. Additional structures tested in this study. Compound Name. Screen Name. CAS #. Structure. 5-(3-Pyridyl)-4H-1,2,4-triazole-3- thiol. OLC16.

Figure S3. - PLOS

Figure S3 - PLOS

Download PDF

5 downloads 220 Views 9MB Size Report

Comment

GM-10. AN-30. S-10. N-30. NN-10. LZD-30. TE-5. MI-30. D-30. T-30. TGC-15. NB-30. ENX-10. GAT-5. CIP-5. LOM-10. SPX-5. LVX-5. MFX-5. EM-50. Figure S3.

Figure S3

M. smegmatis

MsΔmetH Code

GAT-5

TEL-15

CIP-5

ETP-10

TE-5

NN-10

LVX-5

N-30

MFX-5

IPM-10

EM-50

S-10

TGC-15

LOM-10

T-30

CLR-15

LZD-30

AZM-15

ENX-10

GM-10

SPX-5

NB-30

D-30

AN-30

MI-30

Antibiotic Class

ETP-10 IPM-10 CLR-15 AZM-15 TEL-15 GM-10 AN-30 S-10 N-30 NN-10 LZD-30 TE-5 MI-30 D-30 T-30 TGC-15 NB-30 ENX-10 GAT-5 CIP-5 LOM-10

Ertepenem Imipenem Clarithromycin Azithromycin Telithromycin Gentamycin Amikacin Streptomycin Neomycin Tobramycin Linezolid Tetracycline Minocycline Doxycycline Oxytetracycline Tygecycline Novobiocin Enoxacin Gatifloxacin Ciprofloxacin Lomefloxacin

SPX-5 LVX-5 MFX-5

Sparfloxacin Levofloxacin Moxifloxacin

EM-50

Ethambutol

Target

Pathway

Peptidoglycan (PBPs)

Cell wall synthesis

Ribosome

Protein synthesis

Quinolones

DNA gyrase

DNA replication

Antimycobacterials

Arabinogalactan Mycobacterial cell wall synthesis (EmbC)

β-lactams Macrolides

Aminoglycosides

Oxazolidinones Tetracycline antibiotics

Aminocoumarins